
| 2012 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2013 | 0 | 5.994.072 | 143.625 | 1 | ||
| 2012 | 0 | 5.999.642 | 374.978 | 1 | ||
Total number of partners: 32
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 32
Frequent / Rare Partner Ratio: 0
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2013-10-01 | A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer | GANNET53 | participant | 5.994.072 | 18 |
| 2012-10-01 | Rational molecular Assessments and Innovative Drug Selection | RAIDS | participant | 5.999.642 | 16 |